Arcellx, Inc. (ACLX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ACLX
- Company Arcellx, Inc.
- Price $113.79
- Changes Percentage 0.03
- Change 0.04
- Day Low $113.66
- Day High $113.89
- Year High $113.89
- Year Low $47.86
- Market Cap $6,579,427,417
- Price Avg 50 EMA (D) $67.36
- Price Avg 200 EMA (D) $71.93
- Exchange NASDAQ
- Volume 11,457,567
- Average Volume 1,083,556
- Open $113.8
- Previous Close $113.75
- EPS -3.93
- PE -28.95
- Earnings Announcement 2026-02-26 21:00:00
- Shares Outstanding $57,822,871
Company brief: ARCELLX, INC. (ACLX )
- Healthcare
- Biotechnology
- Mr. Rami Elghandour
- https://arcellx.com
- US
- N/A
- 02-04-2022
- US03940C1009
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
ACLX Corporation News
Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders
prnewswire.com -- MILWAUKEE, Feb. 23, 2026 /PRNewswire/ -- Ademi LLP is investigating Arcellx (NASDAQ: ACLX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction wit...
Why is Arcellx stock up 80% today? Gilead's $7.8B answer
invezz.com -- Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock's move wasn't ...
ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com -- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Arcellx, Inc. (NASDAQ: ACLX) to Gilead Sciences, Inc. for $115.00 per share in cash plus one cont...
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
wsj.com -- Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing....
Gilead to acquire Arcellx for $7.8 billion
reuters.com -- Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading....
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
businesswire.com -- FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: AC...